An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Basic Trial Information
|Phase II||Treatment||Active||18 and over||TL139204|
Milataxel is a new taxane that may have several advantages over the currently available
taxanes. The current study is designed to determine the response rate of oral Milataxel in
patients with malignant Mesothelioma. The study specifically targets patients who have
recurring or progressive disease following previous chemotherapy.
Further Study Information
This is a non-randomized, multicenter, open label, single agent phase II study. Patients
with malignant mesothelioma that has recurred or progressed following chemotherapy, and who
qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day cycle.
If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for
the second and subsequent cycles. Patients will receive drug for a total of six cycles.
Milataxel administration in excess of six cycles will be permitted at the discretion of the
Investigator if patients have stable or responding disease.
Patients must have histologically or cytologically confirmed malignant mesothelioma
for which they have received pemetrexed in combination with cisplatin as part of
Prior cancer therapy with pemetrexed/cisplatin must have been completed at least 30
days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the
bone marrow) must have been completed at least 30 days prior to study enrollment.
Patients must have measurable disease by the Modified RECIST criteria
Patients must have a life expectancy of at least 12 weeks and an ECOG performance
status of 0, 1 or 2
Patients must be 18 years of age.
Patients must have adequate organ and system function.
Patients must be able to comply with the protocol treatments and procedures.
Patients with known brain metastases may be included in the study, providing they are
Recovered from all acute toxicities caused by prior cancer therapies, except for
Patients must not have received any other chemotherapeutic treatment for malignant
mesothelioma other than pemetrexed and a platinum agent such as cisplatin.
Patients with grade 2 or greater peripheral neuropathy.
Prior cancer therapies not completed within 30 days prior to the first cycle of
milataxel; radiotherapy completed less than 30 days prior to study enrollment;
patients not recovered from radiation-related toxicities; patients receiving any
concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an
investigational agent while on-study; patients with greater than 2 prior radiotherapy
Patients with known sensitivity to alcohol.
Patients with significant intercurrent illnesses.
Patients with symptomatic CNS metastases.
Patients who have had major surgery within the past 14 days.
Patients who require or are likely to require any strong modifier of CYP450 activity
to be taken prior to milataxel administration
Patients who are receiving high dose steroids (more than a dexamethasone-equivalent
dose of 4 mg per day).
Patients with malabsorption syndrome, disease significantly affecting
gastrointestinal function, or major resection of the stomach or small bowel that
could affect absorption of the study drug.
Women who are pregnant or breastfeeding.
Trial Contact Information
Trial Lead Organizations / Sponsors / Collaborators
Columbia University/Herbert Irving Cancer Center
Robert N. Taub
Robert N. Taub
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00685204
Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.